Search

Your search keyword '"Kaski, Juan Carlos"' showing total 1,814 results
Start Over Author "Kaski, Juan Carlos"
1,814 results on '"Kaski, Juan Carlos"'

4. Changes in circulating ApoJ-Glyc levels in patients with suspected acute coronary syndrome: The EDICA trial

Author

Kaski, Juan Carlos, Lluch, Nuria, Lopez-Sendon, Jose-Luis, Gorog, Diana A., Antorrena-Miranda, Isabel, Avanzas, Pablo, Herrero Puente, Pablo, Sionis, Alessandro, González-Juanatey, José R., Íñiguez, Andrés, Cordero, Alberto, Ako, Emmanuel, Fernández-Avilés, Francisco, Atienza, Felipe, Recio-Mayoral, Alejandro, Wu, Alan H.B., Crea, Filippo, Storey, Robert, Badimon, Lina, and Cubedo, Judit

Published
2023
Full Text
View/download PDF

5. Characteristics of patients with recurrent acute myocardial infarction after MINOCA

Author

Ciliberti, Giuseppe, Guerra, Federico, Pizzi, Carmine, Merlo, Marco, Zilio, Filippo, Bianco, Francesco, Mancone, Massimo, Zaffalon, Denise, Gioscia, Rocco, Bergamaschi, Luca, Compagnucci, Paolo, Armillotta, Matteo, Casella, Michela, Sansonetti, Angelo, Marini, Marco, Paolisso, Pasquale, Stronati, Giulia, Gallina, Sabina, Dello Russo, Antonio, Perna, Gian Piero, Fedele, Francesco, Bonmassari, Roberto, De Luca, Giuseppe, Tritto, Isabella, Piva, Tommaso, Sinagra, Gianfranco, Ambrosio, Giuseppe, Kaski, Juan Carlos, and Verdoia, Monica

Published
2023
Full Text
View/download PDF

13. Oral anticoagulation in patients with left ventricular thrombus – a systematic review and meta-analysis

Author

Haller, Paul M, primary, Kazem, Niema, additional, Agewall, Stefan, additional, Borghi, Claudio, additional, Ceconi, Claudio, additional, Dobrev, Dobromir, additional, Cerbai, Elisabetta, additional, Grove, Erik Lerkevang, additional, Kaski, Juan Carlos, additional, Lewis, Basil S, additional, Niessner, Alexander, additional, Rocca, Bianca, additional, Rosano, Giuseppe, additional, Savarese, Gianluigi, additional, Schnabel, Renate, additional, Semb, Anne Grete, additional, Sossalla, Samuel, additional, Wassmann, Sven, additional, and Sulzgruber, Patrick, additional

Published
2024
Full Text
View/download PDF

15. Results of an international crowdsourcing survey on the treatment of non-ST segment elevation ACS patients at high-bleeding risk undergoing percutaneous intervention

Author

Bhatt, Deepak L., Kaski, Juan Carlos, Delaney, Sean, Alasnag, Mirvat, Andreotti, Felicita, Angiolillo, Dominick J., Ferro, Albert, Gorog, Diana A., Lorenzatti, Alberto J., Mamas, Mamas, McNeil, John, Nicolau, José C., Steg, Philippe Gabriel, Tamargo, Juan, Tan, Doreen, and Valgimigli, Marco

Published
2021
Full Text
View/download PDF

17. Pharmacological therapy for the prevention of cardiovascular events in patients with myocardial infarction with non-obstructed coronary arteries (MINOCA): Insights from a multicentre national registry

Author

Ciliberti, Giuseppe, Verdoia, Monica, Merlo, Marco, Zilio, Filippo, Vatrano, Marco, Bianco, Francesco, Mancone, Massimo, Zaffalon, Denise, Bonci, Alessia, Boscutti, Andrea, Infusino, Fabio, Coiro, Stefano, Stronati, Giulia, Tritto, Isabella, Gioscia, Rocco, Dello Russo, Antonio, Fedele, Francesco, Gallina, Sabina, Cassadonte, Francesco, Ambrosio, Giuseppe, Bonmassari, Roberto, De Luca, Giuseppe, Sinagra, Gianfranco, Capucci, Alessandro, Kaski, Juan Carlos, and Guerra, Federico

Published
2021
Full Text
View/download PDF

18. Myocardial ischaemic syndromes: a new nomenclature to harmonize evolving international clinical practice guidelines.

Author

Boden, William E, Caterina, Raffaele De, Kaski, Juan Carlos, Merz, Noel Bairey, Berry, Colin, Marzilli, Mario, Pepine, Carl J, Barbato, Emanuele, Stefanini, Giulio, Prescott, Eva, Steg, Philippe Gabriel, Bhatt, Deepak L, Hill, Joseph A, and Crea, Filippo

Subjects
MYOCARDIAL ischemia, ACUTE coronary syndrome, CORONARY artery disease, CORONARY disease, ANGINA pectoris, MYOCARDIAL infarction
Abstract

Since the 1960s, cardiologists have adopted several binary classification systems for acute myocardial infarction (MI) that facilitated improved patient management. Conversely, for chronic stable manifestations of myocardial ischaemia, various classifications have emerged over time, often with conflicting terminology—e.g. 'stable coronary artery disease' (CAD), 'stable ischaemic heart disease', and 'chronic coronary syndromes' (CCS). While the 2019 European guidelines introduced CCS to impart symmetry with 'acute coronary syndromes' (ACS), the 2023 American guidelines endorsed the alternative term 'chronic coronary disease'. An unintended consequence of these competing classifications is perpetuation of the restrictive terms 'coronary' and 'disease', often connoting only a singular obstructive CAD mechanism. It is now important to advance a more broadly inclusive terminology for both obstructive and non-obstructive causes of angina and myocardial ischaemia that fosters conceptual clarity and unifies dyssynchronous nomenclatures across guidelines. We, therefore, propose a new binary classification of 'acute myocardial ischaemic syndromes' and 'non-acute myocardial ischaemic syndromes', which comprises both obstructive epicardial and non-obstructive pathogenetic mechanisms, including microvascular dysfunction, vasospastic disorders, and non-coronary causes. We herein retain accepted categories of ACS, ST-segment elevation MI, and non-ST-segment elevation MI, as important subsets for which revascularization is of proven clinical benefit, as well as new terms like ischaemia and MI with non-obstructive coronary arteries. Overall, such a more encompassing nomenclature better aligns, unifies, and harmonizes different pathophysiologic causes of myocardial ischaemia and should result in more refined diagnostic and therapeutic approaches targeted to the multiple pathobiological precipitants of angina pectoris, ischaemia and infarction. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

20. Abstract 13104: Prognostic Value of a Progressive Decrease in Apoj-Glyc Levels in Patients Attending A&E Departments With Suspected Acute Coronary Syndrome or Angina-Like Pain

Author

Kaski, Juan-Carlos C, Cubedo, Judit, Lluch, Nuria, Lopez-sendon, Jose L, Gorog, Diana, Antorrena, Isabel, Avanzas, Pablo, Herrero Puente, Pablo, Sionis, Alessandro, Gonzalez-Juanatey, Jose R, Iñiguez, Andrés, Cordero, Alberto, Ako, Emmanuel, Fernandez-Aviles, Francisco, Atienza, Felipe, Recio-Mayoral, Alejandro, and Badimon, Lina

Published
2022
Full Text
View/download PDF

21. Abstract 13079: Reduced Apoj-Glyc Serum Levels Identify Patients With Cardiac Ischemic Events Among Those Attending the Emergency Department With Chest Pain

Author

Kaski, Juan-Carlos C, Cubedo, Judit, Lluch, Nuria, Lopez-sendon, Jose L, Gorog, Diana, Antorrena, Isabel, Avanzas, Pablo, Herrero Puente, Pablo, Sionis, Alessandro, Gonzalez-Juanatey, Jose R, Iñiguez, Andrés, Cordero, Alberto, Ako, Emmanuel, Fernandez-Aviles, Francisco, Atienza, Felipe, Recio-Mayoral, Alejandro, and Badimon, Lina

Published
2022
Full Text
View/download PDF

23. Heart failure pharmacotherapy and cancer: pathways and pre-clinical/clinical evidence

Author

Sayour, Nabil V, primary, Paál, Ágnes M, additional, Ameri, Pietro, additional, Meijers, Wouter C, additional, Minotti, Giorgio, additional, Andreadou, Ioanna, additional, Lombardo, Antonella, additional, Camilli, Massimiliano, additional, Drexel, Heinz, additional, Grove, Erik Lerkevang, additional, Dan, Gheorghe Andrei, additional, Ivanescu, Andreea, additional, Semb, Anne Grete, additional, Savarese, Gianluigi, additional, Dobrev, Dobromir, additional, Crea, Filippo, additional, Kaski, Juan-Carlos, additional, de Boer, Rudolf A, additional, Ferdinandy, Péter, additional, and Varga, Zoltán V, additional

Published
2024
Full Text
View/download PDF

26. Heart failure pharmacotherapy and cancer:pathways and pre-clinical/clinical evidence

Author

Sayour, Nabil V., Paál, Ágnes M., Ameri, Pietro, Meijers, Wouter C., Minotti, Giorgio, Andreadou, Ioanna, Lombardo, Antonella, Camilli, Massimiliano, Drexel, Heinz, Grove, Erik Lerkevang, Dan, Gheorghe Andrei, Ivanescu, Andreea, Semb, Anne Grete, Savarese, Gianluigi, Dobrev, Dobromir, Crea, Filippo, Kaski, Juan Carlos, de Boer, Rudolf A., Ferdinandy, Péter, Varga, Zoltán V., Sayour, Nabil V., Paál, Ágnes M., Ameri, Pietro, Meijers, Wouter C., Minotti, Giorgio, Andreadou, Ioanna, Lombardo, Antonella, Camilli, Massimiliano, Drexel, Heinz, Grove, Erik Lerkevang, Dan, Gheorghe Andrei, Ivanescu, Andreea, Semb, Anne Grete, Savarese, Gianluigi, Dobrev, Dobromir, Crea, Filippo, Kaski, Juan Carlos, de Boer, Rudolf A., Ferdinandy, Péter, and Varga, Zoltán V.

Abstract

Heart failure (HF) patients have a significantly higher risk of new-onset cancer and cancer-associated mortality, compared to subjects free of HF. While both the prevention and treatment of new-onset HF in patients with cancer have been investigated extensively, less is known about the prevention and treatment of new-onset cancer in patients with HF, and whether and how guideline-directed medical therapy (GDMT) for HF should be modified when cancer is diagnosed in HF patients. The purpose of this review is to elaborate and discuss the effects of pillar HF pharmacotherapies, as well as digoxin and diuretics on cancer, and to identify areas for further research and novel therapeutic strategies. To this end, in this review, (i) proposed effects and mechanisms of action of guideline-directed HF drugs on cancer derived from pre-clinical data will be described, (ii) the evidence from both observational studies and randomized controlled trials on the effects of guideline-directed medical therapy on cancer incidence and cancer-related outcomes, as synthetized by meta-analyses will be reviewed, and (iii) considerations for future pre-clinical and clinical investigations will be provided.

Published
2024

29. Clinical characteristics and long-term prognosis of contemporary patients with vasospastic angina: Ethnic differences detected in an international comparative study

Author

Sato, Koichi, Takahashi, Jun, Odaka, Yuji, Suda, Akira, Sueda, Shozo, Teragawa, Hiroki, Ishii, Katsuhisa, Kiyooka, Takahiko, Hirayama, Atsushi, Sumiyoshi, Tetsuya, Tanabe, Yasuhiko, Kimura, Kazuo, Kaikita, Koichi, Ong, Peter, Sechtem, Udo, Camici, Paolo G., Kaski, Juan Carlos, Crea, Filippo, Beltrame, John F., and Shimokawa, Hiroaki

Published
2019
Full Text
View/download PDF

32. Zibotentan in Microvascular Angina: A Randomized, Placebo-Controlled, Crossover Trial

Author

Morrow, Andrew, Young, Robin, Abraham, George R., Hoole, Stephen, Greenwood, John P., Arnold, Jayanth Ranjit, El Shibly, Mohamed, Shanmuganathan, Mayooran, Ferreira, Vanessa, Rakhit, Roby, Galasko, Gavin, Sinha, Aish, Perera, Divaka, Al-Lamee, Rasha, Spyridopoulos, Ioakim, Kotecha, Ashish, Clesham, Gerald, Ford, Thomas J., Davenport, Anthony, Padmanabhan, Sandosh, Jolly, Lisa, Kellman, Peter, Kaski, Juan Carlos, Weir, Robin A., Sattar, Naveed, Kennedy, Julie, Macfarlane, Peter W., Welsh, Paul, McConnachie, Alex, and Berry, Colin

Published
2024
Full Text
View/download PDF

33. Update on antithrombotic therapy and body mass: a clinical consensus statement of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and the European Society of Cardiology Working Group on Thrombosis

Author

Gigante, Bruna, Tamargo, Juan, Agewall, Stefan, Atar, Dan, ten Berg, Jurrien, Campo, Gianluca, Cerbai, Elisabetta, Christersson, Christina, Dobrev, Dobromir, Ferdinandy, Péter, Geisler, Tobias, Gorog, Diana A, Grove, Erik L, Kaski, Juan Carlos, Rubboli, Andrea, Wassmann, Sven, Wallen, Håkan, and Rocca, Bianca

Abstract

Obesity and underweight are a growing health problem worldwide and a challenge for clinicians concerning antithrombotic therapy, due to the associated risks of thrombosis and/or bleeding. This clinical consensus statement updates a previous one published in 2018, by reviewing the most recent evidence on antithrombotic drugs based on body size categories according to the World Health Organization classification. The document focuses mostly on individuals at the extremes of body weight, i.e. underweight and moderate-to-morbid obesity, who require antithrombotic drugs, according to current guidelines, for the treatment or prevention of cardiovascular diseases or venous thromboembolism. Managing antithrombotic therapy or thromboprophylaxis in these individuals is challenging, due to profound changesin body composition, metabolism and organ function, and altered drug pharmacokinetics and pharmacodynamics, as well as weak or no evidence from clinical trials. The document also includes artificial intelligence simulations derived from in silicopharmacokinetic/pharmacodynamic models, which can mimic the pharmacokinetic changes and help identify optimal regimens of antithrombotic drugs for severely underweight or severely obese individuals. Further, bariatric surgery in morbidly obese subjects is frequently performed worldwide. Bariatric surgery causes specific and additional changes in metabolism and gastrointestinal anatomy, depending on the type of the procedure, which can also impact the pharmacokinetics of antithrombotic drugs and their management. Based on existing literature, the document provides consensus statements on optimizing antithrombotic drug management for underweight and all classes of obese patients, while highlighting the current gaps in knowledge in these complex clinical settings, which require personalized medicine and precision pharmacology.Graphical AbstractRisks of thrombosis and bleeding, antithrombotic drug management, and supporting type of evidence across body size categories. From left to right: a causal relationship between obesity and deep vein thrombosis (DVT) risk has been suggested by Mendelian randomization studies. Generally, DVT risk linearly increases from underweight to the highest body mass index classes. Despite the low risk of underweight individuals, underweight seems to have a worse prognosis once venous thrombosis has occurred. The risk of arterial thrombosis increases from normoweight to severe obesity, while the risk associated with being underweight remains less clear, possibly mimicking a U-shaped relationship. A U-shaped relationship seems to describe the risk of major bleeding associated with body size. However, the anatomical site and type of bleeding, underlying risk factors, and prognosis differ at the two extremes. Optimizing the dosing of antithrombotic drugs both in underweight and class =2 obese individuals is supported by pharmacokinetic/pharmacodynamic (PK/PD) studies and data from post hoc analyses of randomized studies, observational, and registry data as well as by artificial intelligence simulations of in silicoPK/PD models generated by population and randomized clinical trial experimental measurements. In underweight individuals, most evidence indicates better safety of reducing the daily doses of standard, fixed-dose antithrombotic drugs, while increasing the fixed dose is suggested for those in class =2 obesity. For body weight-adjusted antithrombotic drugs, individuals with higher classes of obesity may be overdosed due to a major imbalance between lean and fat mass that has a major impact on drug PK and bioavailability. On the other hand, if capping is us-//-ed, this may result in underdosing at the upper extreme of body size. Further details are reported in the Central Tables 1and 2. LMWH, low-molecular-weight heparin; OAC, oral anticoagulation; UFH, unfractionated heparin.

Published
2024
Full Text
View/download PDF

34. Management of dyslipidaemia in patients with comorbidities: facing the challenge

Author

Mayer, Gert, Dobrev, Dobromir, Kaski, Juan Carlos, Semb, Anne Grete, Huber, Kurt, Zirlik, Andreas, Agewall, Stefan, and Drexel, Heinz

Abstract

Dyslipidaemia is a common chronic kidney disease (CKD) and contributes to excessively elevated cardiovascular mortality. The pathophysiology is complex and modified by comorbidities like the presence/absence of proteinuria, diabetes mellitus or drug treatment. This paper provides an overview of currently available treatment options. We focused on individuals with CKD and excluded those on renal replacement therapy (haemodialysis, peritoneal dialysis, or kidney transplantation). The use of statins is safe and recommended in most patients, but guidelines vary with respect to low-density lipoprotein (LDL) cholesterol goals. While no dedicated primary or secondary prevention studies are available for pro-protein convertase subtilisin/kexin type 9 inhibitors, secondary analyses of large outcome trials reveal no effect modification on endpoints by the presence of CKD. Similar data have been shown for bempedoic acid, but no definite conclusion can be drawn with respect to efficacy and safety. No outcome trials are available for inclisiran while the cholesterol lowering effects seem to be unaffected by CKD. Finally, the value of fibrates and icosapent ethyl in CKD is unclear. Lipid abnormalities contribute to the massive cardiovascular disease burden in CKD. Lowering of LDL cholesterol with statins (and most likely PCSK9 inhibitors) reduces the event rate and thus statin therapy should be initiated in almost all individuals. Other interventions (bempedoic acid, inclisiran, fibrates, or icosapent ethyl) currently need a case-by-case decision before prescription.

Published
2024
Full Text
View/download PDF

35. Precision Pharmacotherapy With Zibotentan in Microvascular Angina: a randomized, placebo-controlled, cross-over trial.

Author

Berry, Colin, primary, Morrow, Andrew, additional, Abraham, George, additional, Hoole, Stephen, additional, Greenwood, John, additional, Arnold, Jayanth, additional, Shanmuganathan, Mayooran, additional, Ferreira, Vanessa, additional, Rakhit, Roby, additional, Galasko, Gavin, additional, Sinha, Aish, additional, Perera, Divaka, additional, Al-lamee, Rasha, additional, Spyridopoulos, Ioakim, additional, Kotecha, Ashish, additional, Clesham, Gerald, additional, Ford, Tom, additional, Davenport, Anthony, additional, Jolly, Lisa, additional, Kellman, Peter, additional, Kaski, Juan-Carlos, additional, Weir, Robin, additional, Sattar, Naveed, additional, Welsh, Paul, additional, Kennedy, Julie, additional, Macfarlane, Peter, additional, McConnachie, Alex, additional, and Shibly, Mohamed El, additional

Published
2023
Full Text
View/download PDF

46. Nicorandil

Author

Tarkin, Jason M., Kaski, Juan Carlos, Kaski, Juan Carlos, Series editor, and Avanzas, Pablo, editor

Published
2015
Full Text
View/download PDF

47. Characterisation of Ferritin–Lymphocyte Ratio in COVID-19

Author

Liu, Alexander, primary, Hammond, Robert, additional, Chan, Kenneth, additional, Chukwuenweniwe, Chukwugozie, additional, Johnson, Rebecca, additional, Khair, Duaa, additional, Duck, Eleanor, additional, Olubodun, Oluwaseun, additional, Barwick, Kristian, additional, Banya, Winston, additional, Stirrup, James, additional, Donnelly, Peter D., additional, Kaski, Juan Carlos, additional, and Coates, Anthony R. M., additional

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results